Kevin H Eng1, Bret M Hanlon2, William H Bradley3, J Brian Szender4. 1. Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, United States. Electronic address: kevin.eng@roswellpark.org. 2. Department of Statistics, University of Wisconsin-Madison, Madison, WI, United States. 3. Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, United States. 4. Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, United States.
Abstract
OBJECTIVES: While primary treatment for high-grade serous ovarian cancer tends to be uniform - maximal debulking and platinum/taxane adjuvant chemotherapy - there is little standardization of treatment in the recurrent setting beyond the exhaustive use of platinum therapies. Using secondary data from multiple centers participating in the Cancer Genome Atlas study (TCGA), we seek to characterize clinical features, timing and serial response data to provide empirical evidence for treatment expectations in the recurrent setting. METHODS: We conducted a retrospective survival analysis of TCGA study primary and secondary patient chemotherapy regimens by characterizing the dynamics of 1119 lines of therapy comprising the treatment of 461 high-grade serous ovarian cancer patients. All patients with post-surgical drug therapy information from the TCGA database were included in this study. RESULTS: A complete response to adjuvant therapy led to longer overall survival, but did not affect treatment free intervals (TFIs) after relapse of disease. A strong predictor of the TFI on the next treatment regimen was the previous TFI with a decaying effect. The number of previous treatments, of platinum treatments, and the length of time from surgery all have an exponentially decreasing effect on TFI. Re-treatment times appear to cluster at predictable times following surgery. CONCLUSIONS: While patients experience a consistent reduction in TFI with increasing re-treatment, the initial adjuvant interval is unrelated to later interval lengths. Platinum re-treatment remained an effective option in patients typically thought to be platinum resistant and the timing of monitoring visits may drive overall re-treatment patterns.
OBJECTIVES: While primary treatment for high-grade serous ovarian cancer tends to be uniform - maximal debulking and platinum/taxane adjuvant chemotherapy - there is little standardization of treatment in the recurrent setting beyond the exhaustive use of platinum therapies. Using secondary data from multiple centers participating in the Cancer Genome Atlas study (TCGA), we seek to characterize clinical features, timing and serial response data to provide empirical evidence for treatment expectations in the recurrent setting. METHODS: We conducted a retrospective survival analysis of TCGA study primary and secondary patient chemotherapy regimens by characterizing the dynamics of 1119 lines of therapy comprising the treatment of 461 high-grade serous ovarian cancerpatients. All patients with post-surgical drug therapy information from the TCGA database were included in this study. RESULTS: A complete response to adjuvant therapy led to longer overall survival, but did not affect treatment free intervals (TFIs) after relapse of disease. A strong predictor of the TFI on the next treatment regimen was the previous TFI with a decaying effect. The number of previous treatments, of platinum treatments, and the length of time from surgery all have an exponentially decreasing effect on TFI. Re-treatment times appear to cluster at predictable times following surgery. CONCLUSIONS: While patients experience a consistent reduction in TFI with increasing re-treatment, the initial adjuvant interval is unrelated to later interval lengths. Platinum re-treatment remained an effective option in patients typically thought to be platinum resistant and the timing of monitoring visits may drive overall re-treatment patterns.
Authors: Michelle L Kurta; Robert P Edwards; Kirsten B Moysich; Kathleen McDonough; Marnie Bertolet; Joel L Weissfeld; Janet M Catov; Francesmary Modugno; Clareann H Bunker; Roberta B Ness; Brenda Diergaarde Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: Robert J Morgan; Ronald D Alvarez; Deborah K Armstrong; Robert A Burger; Mariana Castells; Lee-may Chen; Larry Copeland; Marta Ann Crispens; David Gershenson; Heidi Gray; Ardeshir Hakam; Laura J Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A Matulonis; David M O'Malley; Richard T Penson; Steven W Remmenga; Paul Sabbatini; Joseph T Santoso; Russell J Schilder; Julian Schink; Nelson Teng; Theresa L Werner; Miranda Hughes; Mary A Dwyer Journal: J Natl Compr Canc Netw Date: 2012-11-01 Impact factor: 11.908
Authors: Christopher H Bailey; Gayle Jameson; Chao Sima; Sharon Fleck; Erica White; Daniel D Von Hoff; Glen J Weiss Journal: J Cancer Date: 2011-11-28 Impact factor: 4.207
Authors: Vito Andrea Capozzi; Andrea Rosati; Luigi Carlo Turco; Giulio Sozzi; Matteo Riccò; Benito Chiofalo; Giuseppe Vizzielli Journal: Gland Surg Date: 2020-08
Authors: Christine A Parkinson; Davina Gale; Anna M Piskorz; Heather Biggs; Charlotte Hodgkin; Helen Addley; Sue Freeman; Penelope Moyle; Evis Sala; Karen Sayal; Karen Hosking; Ioannis Gounaris; Mercedes Jimenez-Linan; Helena M Earl; Wendi Qian; Nitzan Rosenfeld; James D Brenton Journal: PLoS Med Date: 2016-12-20 Impact factor: 11.069